Advertisement

BG Medicine, Inc. (BGMD), the maker of an FDA-approved diagnostic test for heart failure, saw its shares fall almost 6 percent Thursday. This followed the company reporting that its second quarter loss widened on increased costs, and that the company withdrew a diagnostic test from FDA consideration.

Advertisement
Advertisement